Vertex Reports long-term follow-up Data for Risdiplam in Gastric cancer

Vertex today announced long-term follow-up results for risdiplam in patients with gastric cancer. The study demonstrated that risdiplam reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of gastric cancer and support the continued development of risdiplam in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.